Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?

J Clin Oncol. 2021 Sep 20;39(27):3089-3090. doi: 10.1200/JCO.21.01174. Epub 2021 Jul 6.

Authors

Yukino Kawamura¹, Akihiko Shimomura¹, Chikako Shimizu¹

Affiliation

¹ Yukino Kawamura, MD, Akihiko Shimomura, MD, PhD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

PMID: 34228507
DOI: 10.1200/JCO.21.01174

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms* / drug therapy
Female
Humans
Neoadjuvant Therapy
Piperazines / adverse effects
Pyridines / adverse effects

Substances

Piperazines
Pyridines
palbociclib